GlassScriptPhysician profile
Amy Kerkela
NPI 1790237840
$1,184.21
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.13 · 2022: $96.53 · 2023: $883 · 2024: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.55 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.24 | 2023-2024 | |
| Astellas Pharma US INC | $136.79 | 2023 | Veozah |
| Lilly USA, LLC | $99.82 | 2023 | Mounjaro, Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $97.02 | 2021-2022 | |
| Axsome Therapeutics, INC. | $88.11 | 2023-2024 | Auvelity |
| Glaxosmithkline, LLC. | $74.18 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Corium, LLC | $63.18 | 2023 | Azstarys |
| Novo Nordisk INC | $42.18 | 2023 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $37.15 | 2024 | Gvoke Hypopen |
| Pfizer INC. | $36.53 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $34.98 | 2023 | Ongentys, Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.92 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.80 | 2023 | Ofev, Jardiance |
| Otsuka America Pharmaceutical, INC. | $30.89 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $22.10 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.00 | 2023 | Verquvo, Belsomra, Januvia |
| Exact Sciences Corporation | $18.02 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $16.91 | 2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $16.82 | 2023 | Farxiga |
| Smith+Nephew, INC. | $16.64 | 2022 | |
| Esperion Therapeutics, INC. | $14.54 | 2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $13.23 | 2023 | Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $13.16 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kerkela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.